Breaking News
FONT-SIZE Plus   Neg
Share SHARE

BioSante Shares Rise On Positive Early Stage Results Of Its Cancer Vaccine

RELATED NEWS
Trade BPAX now with 

BioSante Pharmaceuticals, Inc. (BPAX: Quote) Monday said results from a Phase Ib clinical study of its GVAX Pancreas cancer vaccine showed an over 60 percent increase in the median survival of patients with previously treated, locally advanced or metastatic pancreatic adenocarcinoma or PDA. The results are derived from a comparison with Ipilimumab or IPI.

BioSante said the study was not powered for a direct comparison. The primary endpoint was to determine the safety profile of IPI alone or in combination with GVAX and the secondary endpoints were overall survival and toxicity, and the induction of mesothelin specific T cell responses. BioSante has received Orphan Drug designation from the U.S. Food & Drug Administration for the GVAX Pancreas cancer vaccine.

The median survival when treated with Bristol-Myers Squibb Company Co (BMY: Quote)'s Yervoy (ipilimumab) was 3.3 months. For the combination of IPI plus GVAX Pancreas, the median survival was 5.5 months.

In addition, the IPI/GVAX Pancreas combination demonstrated an increase in one year survival, from 7 percent to 27 percent.

The company said the results demonstrated that toxicities were manageable. In addition, the postimmunotherapy induction of mesothelin-specific T cells in patients correlated with disease-free survival.

The investigators concluded that, "Immunotherapy has potential even in advanced PDA."

Biosante is planning to begin a new multicenter clinical study this year.

BioSante's Pancreas cancer vaccine is made from allogeneic pancreatic cancer cells genetically modified to produce an immune system stimulator, the cytokine GM-CSF, and irradiated to prevent cell growth.

The 30 patient Phase Ib study was conducted by researchers at the Sidney Kimmel Cancer Center of Johns Hopkins University School of Medicine and the Bloomberg School of Public Health at Johns Hopkins, in Baltimore, Maryland.

Stephen Simes, BioSante's president & CEO. "Besides pancreatic cancer, Johns Hopkins researchers also are investigating the use of BioSante's cancer vaccines for the treatment of several different forms of cancer, including leukemia, breast cancer, prostate cancer and melanoma."

About 95 percent of pancreatic cancer is adenocarcinomas. Patients with pancreatic cancer have one of the poorest five-year survival rates of any form of cancer with median survival around three to six months. Pancreatic cancer is sometimes called a "silent killer" because it does not always cause noticeable symptoms and most symptoms are non-specific and varied.

BioSante's products include LibiGel (transdermal testosterone gel) for the treatment of female sexual dysfunction, specifically hypoactive sexual desire disorder or HSDD, which is in Phase III clinical development.

BioSante also is developing a portfolio of cancer vaccines, with 17 Phase I and Phase II clinical trials currently on-going. Four of these vaccines have been granted Orphan Drug designation by the U.S. Food and Drug Administration.

BioSante's first FDA-approved product is Elestrin (estradiol gel) indicated for the treatment of hot flashes associated with menopause, marketed in the U.S. by Jazz Pharmaceuticals, BioSante's licensee.

BPAX is currently trading at $0.86, up $0.15 or 21.11%, on a volume of 13.2 million shares, on the Nasdaq. Over the past year, the stock traded in a range of $0.38 - $4.02, with three-month average volume of 8.3 million shares.

Register
To receive FREE breaking news email alerts for ANI Pharmaceuticals, Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Stocks moved notably higher over the course of the trading day on Friday after initially showing a lack of direction. The gains on the day extended the recent upward trend by the markets, with the tech-heavy Nasdaq reaching its best closing level in almost a month. Looking to capitalize on news of an Ebola diagnosis in New York City, Republican Senate candidate Scott Brown issued a statement Friday criticizing his Democratic opponent Sen. Jeanne Shaheen, D-N.H., for "waffling" on a travel ban. In another troubling sign for Democrats, the results of a Gallup poll released on Friday show that Tea Party Republicans are much more motivated to vote in the upcoming midterm elections than other Americans. The poll found that 73 percent of Tea Party Republicans are "extremely" or "very" motivated to vote in this year's elections.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.